Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Emtricitabine tenofovir price decline?Is switching to herbs safe from lipitor's side effects?Linezolid generic cash price 14 tablets?Oseltamivir nce 1 date patent expiry us fda?Nimodipine stock price?
See the DrugPatentWatch profile for savaysa
Savaysa is a brand of edoxaban, an anticoagulant (blood thinner). It is used to lower the risk of blood clots in certain people, including for prevention of stroke and systemic embolism in patients with atrial fibrillation and for treating and preventing venous thromboembolism (VTE) such as deep vein thrombosis (DVT) and pulmonary embolism (PE).
Doctors typically use Savaysa for: - Atrial fibrillation (AF): to reduce the risk of stroke and systemic embolism in people with AF who meet specific clinical criteria. - VTE treatment: after a person has DVT and/or PE, to treat the clot and then help prevent recurrence. - VTE prevention: in situations where ongoing protection against additional DVT/PE is needed after initial treatment.
Savaysa works by blocking factor Xa, a key step in the body’s clotting pathway. By reducing factor Xa activity, it helps prevent clots from forming and spreading.
Because Savaysa is a blood thinner, the main risk is bleeding. Patients generally need clinician guidance on dosing and monitoring, especially if they have conditions or medications that increase bleeding risk. Sources: 1. DrugPatentWatch.com (Savaysa/edoxaban listings and related information): https://www.drugpatentwatch.com/
Other Questions About Savaysa :